Mdxhealth reported a 13% revenue increase to $27.4 million in Q1 2026 but decided to discontinue its Resolve UTI test and Plano lab due to reimbursement challenges. The company is refocusing on its core prostate cancer diagnostics and integrating AI to enhance its offerings. Despite a net loss of $8.9 million, Mdxhealth expects 20-26% revenue growth in its core cancer business for 2026, excluding Resolve. This strategic shift aims to improve market share and operational efficiency moving forward.
Wrap Technologies reported a 45% revenue increase to $1.1 million in Q1 2026, driven by strong domestic and international demand for its non-lethal BolaWrap 150 product. The company secured a significant purchase order from the U.S. Department of Hom...
Fiserv has agreed with Bridgeport Partners to create a joint venture combining Fiserv’s ATM Managed Services, Cash & Logistics, and MoneyPass businesses. This partnership aims to leverage Fiserv’s industry expertise and Bridgeport’s operational focus...
A new report by Culper Research claims Nvidia's China-related compute business is larger than publicly stated, with over 20% of its 2026 compute revenues allegedly driven by Chinese demand through illegal channels and intermediaries in Southeast Asia...
Berkshire Hathaway, led by CEO Greg Abel, holds a record $380.2 billion in cash, surpassing its $288 billion equity portfolio. The company continues to sell more stocks than it buys, maintaining liquidity to capitalize on future market disruptions. A...
Billionaire investor Daniel Loeb, through Third Point LLC, increased holdings in construction stocks APi Group and MasTec during Q4 FY25, acquiring 3 million shares of APi Group and adding 200,000 shares of MasTec. Meanwhile, he cut his stake in Comf...
